Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 7, October, p. 1101–1106

doi: 10.17219/acem/68978

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Chest HRCT findings in patients with primary Sjögren’s syndrome

Agata Sebastian1,A,B,C,D,E,F, Maria Misterska-Skóra1,E,F, Jurand Silicki2,D, Maciej Sebastian3,D, Piotr Wiland1,E,F

1 Department of Rheumatology and Internal Medicine, Wroclaw Medical University, , Poland

2 Department of General and Pediatric Radiology, Wroclaw Medical University, Poland

3 Department of Minimally Invasive Surgery and Proctology, Wroclaw Medical University, Poland

Abstract

Background. Pulmonary manifestations (PMs) in primary Sjögren’s syndrome (pSS) are among the most frequent extraglandular complications, with reported prevalence varying widely (9–75%), depending on the methods of detection.
Objectives. The aim of this study was to assess the incidence of PMs in pSS and to determine the factors predisposing to the occurrence of this complication.
Material and Methods. The study group consisted of 68 patients with pSS. Among the patients who were possibly affected by PMs, chest High Resolution Computed Tomography (HRCT) was performed.
Results. In the group of all patients afflicted with pSS, 30 people indicated the need to expand medical imaging via chest HRCT scan. (The most frequent reason, in 80%, was persistent, dry cough periodically waking up patients at night). The chest HRCT scan revealed lung tissue changes in the course of 29% of all examined patients (of 68). No correlation was found between the occurrence of HRCT changes and the age of patients (p = 0.8), increased CRP > 5 mg/1 (p = 0.1) or ESR > 20 mm/h (p = 0.9), focus score (p = 0.8), leucopenia (p = 0.5), RF value (p = 0.3), gamma globulin value (p = 0.5), intensity of eye and oral cavity dryness (p = 0.6; 0.3) and smoking cigarettes. Additionally, no correlation was found between more frequent occurrences of antibodies anti-SSA, anti-SSB or anti-Ro52 and HRCT changes (p = 0.3; 0.07; 0.4). Pertaining to the clinical signs, HRCT changes occurred more often only in patients suffering from peripheral arthritis (p < 0.01).
Conclusion. PM is a frequent symptom of pSS. A factor predisposing to the development of changes in the respiratory system was not found. Changes in HRCT occur more frequently in patients with peripheral arthritis.

Key words

chest HRCT, primary Sjogren’s syndrome, pulmonary manifestation

References (24)

  1. Mavragani CP, Moutsopoulos HM. The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev. 2010;9:305–310.
  2. Yazisiz V, Arslan G, Ozbudak IH, et al. Lung involvement in patients with primary Sjögren’s syndrome: What are the predictors? Rheumatol Int. 2010;30:1317–1324.
  3. Chen MH, Chou HP, Lai CC, et al. Lung involvement in primary Sjögren’s syndrome: Correlation between high-resolution computed tomography score and mortality. J Chin Med Assoc. 2014;77:75–82.
  4. Palm O, Garen T, Berge Enger T, et al. Clinical pulmonary involvement in primary Sjögren’s syndrome: Prevalence, quality of life and mortality – a retrospective study based on registry data. Rheumatol. 2013;52:173–179.
  5. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjögren’s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis. 2010;69:1103–1109.
  6. Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. doi: 10.1136/annrheumdis-2014-206008.
  7. Ramos-Casals M, Brito-Zero´n P, Solans R, et al. Systemic involvement in primary Sjogren’s syndrome evaluated by the EULAR-SS disease activity index: Analysis of 921 Spanish patients. Rheumatology. 2014;53:321–331.
  8. Vitali C, Bombardieri S, Jonsson S, et al. Classification criteria for Sjögren’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554–558.
  9. Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren’s syndrome treated with rituximab. Ann Rheum Dis. 2012;71:1297–1302.
  10. Papiris SA, Maniati M, Constantopoulos SH, Roussos C, Moutsopoulos HM, Skopouli FN. Lung involvement in primary Sjögren’s syndrome is mainly related to the small airway disease. Ann Rheum Dis. 1999;58:61–64.
  11. Hatron PY, Tillie-Leblond I, Launay D, Hachulla E, Fauchais AL, Wallaert B. Pulmonary manifestations of Sjögren’s syndrome. Presse Med. 2011;40:49–64.
  12. Egashira R, Kondo T, Hirai T, et al. CT findings of thoracic manifestations of primary Sjögren syndrome: Radiologic-pathologic correlation. RadioGraphics. 2013;33:1933–1949.
  13. Bellido-Casado J, Plaza V, Díaz C, et al. Bronchial inflammation, respiratory symptoms and lung function in primary Sjögren’s syndrome. Arch Bronconeumol. 2011;47:330–334.
  14. Yazisiz V, Arslan G, Ozbudak IH, et al. Lung involvement in patients with primary Sjögren’s syndrome: What are the predictors? Rheumatol Int. 2010;30:1317–1324.
  15. Fox RI, Kang H, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjogren’s syndrome. J Immunol. 1994;152:5532–5539.
  16. Moriyama M, Hayashida JN, Toyoshima T, et al. Cytokine/chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjögren’s syndrome. Clin Exp Immunol. 2012;169:17–26.
  17. Zhang R, Sun T, Song L, Zuo D, Xiao W. Increased levels of serum galectin-3 in patients with primary Sjögren’s syndrome: Associated with interstitial lung disease. Cytokine. 2014;69:289–293.
  18. Yang L, Bai L, Wei F, et al. Autoantibodies against interferon- γ reduce the frequency of pulmonary fibrosis and concentration of C-reactive protein in patients with primary Sjögren’s syndrome. Mod Rheumatol. 2014:1439–7595.
  19. Nannini C, Jebakumar AJ, Crowson CS, Ryu JH, Matteson EL. Primary Sjögren’s syndrome 1976–2005 and associated interstitial lung disease: A population-based study of incidence and mortality. BMJ. 2013;3:e003569.
  20. Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR. Interstitial lung disease in primary Sjögren’s syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med. 1996;154:794–799.
  21. Ogasawara H, Sekiya M, Murashima A, et al. Very low-dose cyclosporine treatment of steroid-resistant interstitial pneumonitis associated with Sjoögren’s syndrome. Clin Rheumatol. 1998;17:160–162.
  22. Emmungil H, Kalfa M, Zihni FY, et al. Interstitial cystitis: A rare manifestation of primary Sjogren’s syndrome, successfully treated with low dose cyclosporine. Rheumatol Int. 2012;32:1215–1218.
  23. Brito-Zero´n P, Siso´-Almirall A, Bove A, Kostov BA, Ramos-Casals M. Primary Sjögren syndrome: An update on current pharmacotherapy options and future directions. Expert Opin Pharmacother. 2013;14:279–289.
  24. Zhan L, Mo H, Zhu M. Effect of cyclophosphamide on cytokines in patients with primary Sjögren’s syndrome-associated interstitial lung disease in South China. Rheumatol Int. 2013;33:1403–1407.